 |
인쇄하기
취소
|
Avandia to be withdrawn from market
GlaxoSmithKline’s blockbuster anti-diabetic agent Avandia (rosiglitazone) will be banned from sales in the Korean market due to its possible cardiovascular risks.
The Korea Food and Drug Administration said on September 24 it has ordered the Health Insurance Review and Assessment Service to enforce stricter monitoring of Avandia’s prescription and usage.
On the same day, the drug agency o...
The Korea Food and Drug Administration said on September 24 it has ordered the Health Insurance Review and Assessment Service to enforce stricter monitoring of Avandia’s prescription and usage.
On the same day, the drug agency o...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.